Viropro Inc. announced that it has a new Board of Directors as a result of an order of the Supreme Court of the State of New York in a challenge by a majority of the Viropro shareholders to the management of company. On May 27, 2014 in a case styled Spring Hill Bioventures SDN BHD, derivatively and on behalf of company v. Cynthia Ekberg Tsai and Richard Serbin (Index No. 654167/2013), New York State Supreme Court Justice Eileen Bransten ordered that the will of the majority of company shareholders in a written consent dated March 27, 2014 be enforced and that Cynthia Ekberg Tsai and Richard Serbin, whose terms as directors had expired, be replaced by Bruce A. Cohen, Kenneth A. Sorensen and Michelle L. E. Peake.

In addition, Justice Bransten ordered Cynthia Ekberg Tsai, the President and CEO of company at the time of this court Order, to turn over all documents and incidents of control over company, including all information about company's accounts and access to them, to the new Board of Directors. The new Board of Directors terminated Cynthia Ekberg Tsai as President and CEO of company and appointed Joseph J. Vallner as Acting President and Bruce A. Cohen as Chairman of the Board. Dr. Vallner has served as Founder and CEO of ORUUS Pharma and CEO of Lumera Corp.

Dr. Vallner was its CEO, and President and CEO of Capnia. Dr. Vallner previously served as President and COO of Gell Genesys and as EVP and COO of SEQUUS Pharmaceuticals. Mr. Cohen was the founding President and CEO of Acacia BioSciences, Cellerant Therapeutics and VitaPath Genetics.

He also served as CFO of GeneSoft Pharmaceuticals, VP at SEQUUS Pharmaceuticals and in several positions at Baxter. Mr. Cohen was the President and COO of ViTel International and a management consultant with Monitor company.